maaf email atau password anda salah

Financial Fraud in Indofarma

Monday, June 3, 2024

The BPK detected Rp371.83 billion worth of fund diversion at Indofarma. Money from a number of subsidiaries was siphoned off through problematic transactions.

arsip tempo : 172147970178.

Illustration by TEMPO/Alvin Siregar. tempo : 172147970178.

AN audit by the Supreme Audit Agency (BPK) finally uncovered the rot within the management of Indofarma, a state-owned company engaged in the production of pharmaceuticals and medical equipment. At the end of 2023, state auditors conducted a special purpose audit (PDTT). During the initial audit, they found irregularities indicating criminal activities, otherwise known as fraud.

The BPK then raised the status of its audit of Indofarma and all it


Subscribe to continue reading.
We craft news with stories.

For the benefits of subscribing to Digital Tempo, See More

The Best Choice

Rp 54.945/Month

Active for 12 Months, Rp 659.340

  • *You Save -Rp 102.000
  • *Guaranteed update of up to 52 Editions of Tempo Magazine

Rp 64.380/Month

Active Every Month Cancel Anytime

  • *Free for the first month if using a Credit Card

See Other Packages

Already a Subscribed? Log in here
To receive daily news by Email, Sign up for Tempo ID.
Bagus Pribadi contributed to this article.

More Articles

More exclusive contents

  • July 15, 2024

  • July 8, 2024

  • July 1, 2024

  • June 24, 2024

Independent journalism needs public support. By subscribing to Tempo, you will contribute to our ongoing efforts to produce accurate, in-depth and reliable information. We believe that you and everyone else can make all the right decisions if you receive correct and complete information. For this reason, since its establishment on March 6, 1971, Tempo has been and will always be committed to hard-hitting investigative journalism. For the public and the Republic.

Login Subscribe